Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li,

Published byΦίλων Ἀρταξέρξης Παχής Modified over 5 years ago

Similar presentations

Presentation on theme: "Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li,"— Presentation transcript:

1 Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li, PhD, Tao Jiang, MD, Huikang Xie, MD, Zhengfei Zhu, MD, PhD, Fei Zhou, MD, Caicun Zhou, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 7, Pages (July 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Programmed death ligand 1 (PD-L1) expression was up-regulated in cell lines after conventionally fractionated radiotherapy. (A) Growth inhibition of the A549, A459/X, A549/DDP, PC9, PC9/R, and H520 cell lines after delivery of 2 Gy of radiation per fraction by clone formation assay. (B) The expression of PD-L1 in these six cell lines by Western blot. (C) The expression of PD-L1 after conventionally fractionated radiotherapy (0, 2, 4, and 6 Gy in 2 Gy per fraction). (D) The expression of PD-L1 was increased after 6 Gy was delivered in three fractions in vitro by flow cytometry. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Down-regulating programmed death ligand 1 (PD-L1) could alleviate radiation resistance by promoting apoptosis. (A and B) Radiotherapy plus anti–PD-L1 therapy significantly inhibited cell migration in A549/X cell lines. (C) Apoptosis rates of A549, A549-si-PD-L1, A549/X, and A549X/si-PD-L1 cell lines by flow cytometry. (D) Apoptosis-related proteins of A549, A549-si-PD-L1, A549/X, and A549X/si-PD-L1 cell lines. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Radiotherapy may up-regulate programmed death ligand 1 (PD-L1) through the phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3 (STAT3) pathways. (A) The expression of PD-L1, p-AKT, p-STAT3, and nuclear factor kappa B (NF-κB) of A549/X in A549, A549-si-PD-L1, A549/X, and A549X/si-PD-L1 cell lines. (B) The expression of of E-cadherin, vimentin, Snail, and N-cadherin in A549, A549-si-PD-L1, A549/X, and A549X/si-PD-L1 cell lines. (C) The expression of PD-L1, transforming growth factor-β (TGF-β), and tripartite motif containing 21 (TRIM21) in A549, A549-si-PD-L1, A549/X, and A549X/si-PD-L1 cell lines. (D) TRIM 21 may directly bond with PD-L1 via immunoprecipitation. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Radiotherapy in combination with anti–programmed death ligand 1 (PD-L1) antibody synergistically enhanced antitumor immunity by reducing the accumulation of myeloid-derived suppressor cells and tumor-infiltrating regulatory T cells and promoting the accumulation of CD8-positive T cells. (A) Radiotherapy (6 Gy delivered in three fractions, once a day) in combination with anti–PD-L1 antibody effectively enhanced the inhibition of tumor growth when compared with anti–PD-L1 alone (p < 0.01) and radiotherapy alone (p < 0.01). (B–E) The expression of PD-L1, CD8-positive T cells, tumor-infiltrating regulatory T cells (CD4 positive, Fox3p-positive), and myeloid-derived suppressor cells (LyGr-positive, CD11b-positive) in a Lewis lung cancer model treated with anti–PD-L1 alone, radiotherapy alone, anti–PD-L1 plus radiotherapy, and vehicle. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 5 Two representative cases revealing the correlation between programmed death ligand 1 (PD-L1) expression and response to radiotherapy. (A) Patient A with negative PD-L1 expression (IHC 0), who achieved a partial response to radiotherapy, had accumulated CD8-positive T-cell infiltration (IHC 3), reduced tumor-infiltrating regulatory T cells (IHC 1), and myeloid-derived suppressor cells (IHC 1). (B) Patient B with PD-L1 overexpression (IHC 2), who achieved stable disease in response to radiotherapy, had reduced CD8-positive T-cell infiltration (IHC 1) and accumulated tumor-infiltrating regulatory T cells (IHC 3) and myeloid-derived suppressor cells (IHC 3). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li,"

Similar presentations

Induction of Forkhead Class box O3a and apoptosis by a standardized ginsenoside formulation, KG-135, is potentiated by autophagy blockade in A549 human.

Induction of Forkhead Class box O3a and apoptosis by a standardized ginsenoside formulation, KG-135, is potentiated by autophagy blockade in A549 human.
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma  Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma  Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer  Tao Jiang,

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer  Tao Jiang,
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Integrin αvβ6 Promotes Lung Cancer Proliferation and Metastasis through Upregulation of IL-8–Mediated MAPK/ERK Signaling  Pengwei Yan, Huanfeng Zhu, Li.

Integrin αvβ6 Promotes Lung Cancer Proliferation and Metastasis through Upregulation of IL-8–Mediated MAPK/ERK Signaling  Pengwei Yan, Huanfeng Zhu, Li.
WT1 Promotes Invasion of NSCLC via Suppression of CDH1

WT1 Promotes Invasion of NSCLC via Suppression of CDH1
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Twist-related protein 1 negatively regulated osteoblastic transdifferentiation of human aortic valve interstitial cells by directly inhibiting runt-related.

Twist-related protein 1 negatively regulated osteoblastic transdifferentiation of human aortic valve interstitial cells by directly inhibiting runt-related.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression.

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression.
Cancer Immunotherapy by Dendritic Cells

Cancer Immunotherapy by Dendritic Cells
IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling  Yuan-Hua Xu, Zheng-Li Li,

IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling  Yuan-Hua Xu, Zheng-Li Li,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation 

Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation 
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 

Similar presentations

Ads by Google